Definitive Contract 75F40126C00122

<p>The Food and Drug Administration issued a purchase order to Parenteral Drug Association, Inc. for $74,916.00 on September 14, 2026, to support the Parenteral Drug Association/Food and Drug Administration Joint Regulatory Conference 2026 under Executive Order 14398. Place of performance is Washington, DC. The order carries a firm fixed price structure with an ultimate completion date of September 16, 2026. No small business set-aside applies.</p>

<p>The Food and Drug Administration awarded a purchase order to Baylor University for $50,000.00 on August 28, 2026, with completion by August 27, 2027. The order is firm fixed price with no set-aside designation. Work is performed in Silver Spring, Maryland.</p>

<p>The Food and Drug Administration issued a delivery order to Nati-Nve Support Services, LLC on May 30, 2026, with a ceiling value of $35.147873 million for routine support services and operations and maintenance of MRC operations under the &quot;EO 14398&quot; program. The order is set aside for Total Small Business and carries a firm fixed price. Place of performance is Laurel, MD, with an ultimate completion date of March 29, 2031.</p>

<p>The Food and Drug Administration issued a $119,668 delivery order to Eastern Research Group Inc. on August 29, 2023, for data on standards of practice in 503B outsourcing facilities under the FDA's Economic Studies of FDA Regulations Indefinite Delivery Contract.</p> <p>Place of performance is Silver Spring, MD. The order was firm fixed price with an ultimate completion date of September 14, 2025.</p>

The Food and Drug Administration issued a $380,540 delivery order to Molecular Epidemiology Inc., a woman-owned small business, on September 1, 2026, for microbial survey of FDA-regulated foods, agricultural water, and cosmetics. The order is issued under an FDA IDIQ contract for microbiological analysis services. Place of performance is Berwyn Heights, MD. The order is firm fixed price with an ultimate completion date of August 31, 2028. No set-aside was used for this delivery order.

<p>The Food and Drug Administration awarded a $995,374 definitive contract to The Task Force For Global Health, Inc. on September 1, 2026, for developing standardized case definitions for adverse events under BAA FY2600123.</p> <p>Place of performance is Decatur, GA. The contract concludes on August 31, 2027, on a firm fixed-price basis with no set-aside applied.</p>

<p>The Food and Drug Administration awarded a $332,866 definitive contract to The Milken Institute on September 10, 2024, for research defining the value and return on investment of patient engagement in medical technology product development under Executive Order 14398.</p> <p>Place of performance is Silver Spring, MD. The contract carries firm fixed price terms and an ultimate completion date of November 30, 2026. No set-aside was used.</p>

<p>The Food and Drug Administration awarded a $933,070.07 definitive contract to the State of Washington Department of Agriculture for human food inspection services on September 10, 2024, with an ultimate completion date of September 29, 2025.</p> <p>Place of performance is Olympia, WA. The contract is firm fixed price with no set-aside applied. The originating solicitation, posted January 18, 2023, sought human food inspection capabilities to support FDA regulatory objectives.</p>

<p>The Food and Drug Administration issued a purchase order to Yale University valued at $137,780 on September 28, 2022, to collect pathologist annotations. This modification de-obligates excess funds and closes out the contract. Work is performed in Silver Spring, Maryland, with an ultimate completion date of September 28, 2027. The purchase order carries firm fixed price pricing with no set-aside applied.</p>

The Food and Drug Administration awarded a definitive contract to The Johns Hopkins University for $517,607 on September 10, 2025, to support the Biologics Effectiveness and Safety Innovative Methods (BEST IM) program, which enhances the safety of vaccines, blood products, and biologics through high-quality analytical methods. This award derives from the FDA's Fiscal Year 2025 Broad Agency Announcement for Advanced Research and Development of Regulatory Science, posted October 3, 2024, with...